{
  "id": "E6n6NFm_15",
  "conversations": [
    {
      "from": "gpt",
      "value": "Multiple myeloma is a type of cancer that arises from malignant plasma cells in the bone marrow. As a result, the identification of tumor-specific antigens (TSA) in myeloma has been challenging due to the lack of highly specific markers that distinguish malignant plasma cells from normal plasma cells.\n\nHowever, recent studies have identified several candidate TSA in multiple myeloma, including:\n\n1. MAGE-A antigens: Melanoma-associated antigen A (MAGE-A) is a group of tumor-specific antigens that are highly expressed in various cancers, including myeloma. MAGE-A antigens are attractive targets for immunotherapy because they are not expressed on normal cells, and they have been shown to elicit strong immune responses in myeloma patients.\n2. NY-ESO-1: NY-ESO-1 is another tumor-specific antigen that is expressed in multiple myeloma cells. NY-ESO-1 is not expressed in normal tissues, except for the testis, which makes it an attractive target for cancer immunotherapy.\n3. WT1: Wilms' tumor 1 (WT1) is a transcription factor that is overexpressed in many cancers, including myeloma. Although WT1 is also expressed in normal cells, its high expression level in myeloma cells makes it a potential target for immunotherapy.\n4. XBP1: X-box binding protein 1 (XBP1) is a transcription factor that is essential for plasma cell differentiation and survival. XBP1 has been shown to be overexpressed in myeloma cells, and it is a potential target for immunotherapy.\n\nThese TSA are being actively investigated as targets for cancer immunotherapy in multiple myeloma, including in clinical trials of CAR T-cell therapy and other immunotherapies.",
      "language": "en",
      "sentiment": {
        "neg": 0.067,
        "neu": 0.876,
        "pos": 0.056,
        "compound": -0.7096
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 287,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 42,
        "adj_adv_ratio": 0.14634146341463414,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 287
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 19.133333333333333,
          "clause_complexity": 0.13333333333333333,
          "vocabulary_richness": 0.5594405594405595
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 2,
            "causality": 1,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBZ": 16,
            "VBN": 14,
            "VBG": 6,
            "VBP": 7,
            "VB": 2
          },
          "named_entities": {
            "GPE": 1,
            "ORGANIZATION": 6,
            "PERSON": 1
          }
        }
      }
    },
    {
      "from": "human",
      "value": "So... BCMA can also be found on healthy plasma cells - correct?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 0.803,
        "pos": 0.197,
        "compound": 0.4019
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 14,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 3,
        "adj_adv_ratio": 0.21428571428571427,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 14
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 14.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 1,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VB": 1,
            "VBN": 1
          },
          "named_entities": {}
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "Yes, that's correct. B-cell maturation antigen (BCMA) is a protein that is expressed on the surface of plasma cells, which are a type of white blood cell that produces antibodies. BCMA is important for the survival and function of plasma cells, and it is also expressed on normal B cells at lower levels.\n\nIn multiple myeloma, BCMA is overexpressed on malignant plasma cells, which makes it an attractive target for immunotherapy. However, targeting BCMA can also affect normal plasma cells and B cells, which can lead to side effects such as reduced antibody production and increased risk of infections.\n\nTo minimize these side effects, researchers are developing strategies to target BCMA specifically on myeloma cells while sparing normal cells. For example, CAR T-cell therapy targeting BCMA can be designed with a binding domain that selectively recognizes BCMA on myeloma cells but not on normal plasma cells or B cells. Similarly, bispecific antibodies and antibody-drug conjugates can be engineered to target BCMA selectively on myeloma cells while sparing normal cells.\n\nOverall, BCMA is a promising target for immunotherapy in multiple myeloma, but its expression on normal plasma cells and B cells must be carefully considered to minimize potential side effects.",
      "language": "en",
      "sentiment": {
        "neg": 0.015,
        "neu": 0.926,
        "pos": 0.058,
        "compound": 0.7845
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 223,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 31,
        "adj_adv_ratio": 0.13901345291479822,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 223
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 24.77777777777778,
          "clause_complexity": 0.2222222222222222,
          "vocabulary_richness": 0.5564516129032258
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 4,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 3,
            "contrast": 3,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBZ": 10,
            "VBN": 6,
            "VBP": 2,
            "VBG": 5,
            "VB": 10,
            "VBD": 1
          },
          "named_entities": {
            "ORGANIZATION": 10
          }
        }
      }
    },
    {
      "from": "human",
      "value": "CD38... same thing",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 1.0,
        "pos": 0.0,
        "compound": 0.0
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 4,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 1,
        "adj_adv_ratio": 0.25,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 4
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 4.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {},
          "named_entities": {
            "GPE": 1
          }
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "CD38 is a protein that is expressed on the surface of many different types of cells, including immune cells and plasma cells. In multiple myeloma, CD38 is overexpressed on malignant plasma cells, which makes it an attractive target for immunotherapy.\n\nHowever, like BCMA, CD38 is also expressed on normal plasma cells and other cells, which can lead to side effects if targeted by immunotherapy. CD38 is important for the regulation of calcium signaling and immune cell function, and targeting it can affect normal immune cell function and lead to side effects such as immunosuppression and increased risk of infections.\n\nTo minimize these side effects, researchers are developing strategies to target CD38 selectively on myeloma cells while sparing normal cells. For example, monoclonal antibodies such as daratumumab and isatuximab have been developed to target CD38 on myeloma cells while minimizing binding to CD38 on normal cells. These antibodies can induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to selectively kill myeloma cells expressing CD38.\n\nOverall, CD38 is a promising target for immunotherapy in multiple myeloma, but its expression on normal cells must be carefully considered to minimize potential side effects.",
      "language": "en",
      "sentiment": {
        "neg": 0.022,
        "neu": 0.902,
        "pos": 0.076,
        "compound": 0.6858
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 213,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 27,
        "adj_adv_ratio": 0.1267605633802817,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 213
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 26.625,
          "clause_complexity": 0.375,
          "vocabulary_richness": 0.5714285714285714
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 3,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 3,
            "contrast": 2,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBZ": 7,
            "VBN": 7,
            "VBG": 7,
            "VB": 11,
            "VBD": 1,
            "VBP": 2
          },
          "named_entities": {
            "ORGANIZATION": 12
          }
        }
      }
    },
    {
      "from": "human",
      "value": "I understand that the theory of complimentary speaks towards the complementing configuration between the antigen and antibody - is that correct?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 0.873,
        "pos": 0.127,
        "compound": 0.4404
      },
      "core_lexical": {
        "self_ref_freq": 1,
        "second_person_freq": 0,
        "token_count": 22,
        "self_ref_ratio": 0.045454545454545456,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 1,
        "adj_adv_ratio": 0.045454545454545456,
        "self_ref_freq": 1,
        "self_ref_ratio": 0.045454545454545456,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 22
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 22.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBP": 1,
            "VBG": 1,
            "VBZ": 1
          },
          "named_entities": {}
        }
      },
      "expressive_label": 1,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "Yes, that's correct. The theory of complementarity, also known as the lock-and-key model, explains how antibodies recognize and bind to specific antigens. According to this theory, the shape of the antigen and the shape of the antibody's binding site complement each other, much like a lock and key.\n\nThe binding site of an antibody is highly specific and recognizes a particular region of the antigen, known as the epitope. When the antibody's binding site and the antigen's epitope fit together, they form a stable complex, which triggers a series of immune responses that can lead to the destruction of the antigen.\n\nThe theory of complementarity is a fundamental principle in immunology and has been extensively studied and validated by experimental evidence. It helps to explain how the immune system can recognize and respond to a vast array of different antigens, even those with highly specific and unique structures.",
      "language": "en",
      "sentiment": {
        "neg": 0.023,
        "neu": 0.861,
        "pos": 0.116,
        "compound": 0.9022
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 168,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 22,
        "adj_adv_ratio": 0.13095238095238096,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 168
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 24.0,
          "clause_complexity": 0.14285714285714285,
          "vocabulary_richness": 0.7341772151898734
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 2,
            "why": 0,
            "can_could": 2,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBZ": 8,
            "VBN": 5,
            "VBP": 3,
            "VBG": 2,
            "VB": 4
          },
          "named_entities": {}
        }
      }
    },
    {
      "from": "human",
      "value": "For TSA such as NY-ESO-1 , how is the complimentary receptor (with correct configuration) made?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 0.828,
        "pos": 0.172,
        "compound": 0.4404
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 18,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 3,
        "adj_adv_ratio": 0.16666666666666666,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 18
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 18.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 1,
            "why": 0,
            "can_could": 0,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 1,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBZ": 1,
            "VBD": 1
          },
          "named_entities": {
            "ORGANIZATION": 1
          }
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "To generate a complimentary receptor that can recognize and bind to a tumor-specific antigen (TSA) such as NY-ESO-1, researchers typically use one of several methods of protein engineering.\n\nOne approach is to use phage display technology, which involves creating a large library of antibody fragments and screening them for those that can bind to the TSA of interest. In this method, the library of antibody fragments is fused to a bacteriophage, a virus that infects bacteria, and the bacteriophage displaying the antibody fragment is used to screen for binding to the TSA.\n\nAnother approach is to use hybridoma technology, which involves fusing B cells from an immunized animal with a tumor cell to create hybrid cells that produce monoclonal antibodies specific to the TSA. Monoclonal antibodies are highly specific and can be used for various immunotherapeutic approaches, including antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapy.\n\nIn CAR T-cell therapy, for example, T cells are genetically engineered to express a chimeric antigen receptor that combines the specificity of an antibody with the cytotoxic activity of a T cell. The CAR recognizes the TSA on the surface of the cancer cells and activates the T cell to destroy the tumor cells.\n\nOverall, generating a complimentary receptor that can recognize and bind to a TSA requires a combination of protein engineering and screening methods to identify specific and effective binding molecules. These technologies continue to evolve and improve, leading to the development of new and more effective immunotherapeutic approaches for cancer.",
      "language": "en",
      "sentiment": {
        "neg": 0.063,
        "neu": 0.857,
        "pos": 0.081,
        "compound": 0.4576
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 278,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 24,
        "adj_adv_ratio": 0.08633093525179857,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 278
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 30.88888888888889,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.6338028169014085
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 4,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 2,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VB": 16,
            "VBP": 6,
            "VBZ": 11,
            "VBG": 9,
            "VBN": 5
          },
          "named_entities": {
            "ORGANIZATION": 9
          }
        }
      }
    },
    {
      "from": "human",
      "value": "So the CAR must fit (like a key) and bind to the antigen. Both the fitting and the binding must be engineered by these methods. Correct?",
      "language": "en",
      "sentiment": {
        "neg": 0.0,
        "neu": 0.828,
        "pos": 0.172,
        "compound": 0.6124
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 31,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 1,
        "adj_adv_ratio": 0.03225806451612903,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 31
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 10.333333333333334,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.9230769230769231
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VB": 3,
            "VBN": 1
          },
          "named_entities": {
            "ORGANIZATION": 1
          }
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "Yes, that's correct. In CAR T-cell therapy, the chimeric antigen receptor (CAR) is engineered to recognize and bind to the tumor-specific antigen (TSA) on the surface of the cancer cells. The CAR is composed of an extracellular domain that contains a binding domain specific to the TSA, a transmembrane domain, and an intracellular domain that activates the T cell.\n\nThe binding domain of the CAR is typically derived from a monoclonal antibody or antibody fragment that has been engineered to recognize and bind to the TSA with high specificity and affinity. This binding domain must fit the TSA like a key and bind to it with high affinity to ensure that the CAR T cells specifically target the cancer cells expressing the TSA.\n\nThe design and engineering of the CAR is a complex process that requires careful consideration of factors such as the specificity, affinity, and stability of the binding domain, as well as the optimal configuration and function of the intracellular signaling domains. The engineering of the CAR is typically done through a combination of molecular biology and protein engineering techniques, including gene editing, cloning, and expression, and is followed by extensive in vitro and in vivo testing to evaluate the efficacy and safety of the CAR T cells.\n\nOverall, the development of CAR T-cell therapy requires careful engineering of both the binding domain of the CAR and the intracellular signaling domains to ensure effective and specific recognition and destruction of cancer cells expressing the TSA.",
      "language": "en",
      "sentiment": {
        "neg": 0.061,
        "neu": 0.842,
        "pos": 0.097,
        "compound": 0.5719
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 272,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 27,
        "adj_adv_ratio": 0.09926470588235294,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 272
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 34.0,
          "clause_complexity": 0.0,
          "vocabulary_richness": 0.5895522388059702
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 2,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBZ": 12,
            "VBN": 7,
            "VB": 8,
            "VBG": 6,
            "VBP": 1
          },
          "named_entities": {
            "ORGANIZATION": 16
          }
        }
      }
    },
    {
      "from": "human",
      "value": "In this case, it would seem to me that the signalling is done to the TCell. That when the receptor changes configuration after binding, this signals the T-cell to release cytokines, which destroy the cancer. Is that correct?",
      "language": "en",
      "sentiment": {
        "neg": 0.18,
        "neu": 0.82,
        "pos": 0.0,
        "compound": -0.836
      },
      "core_lexical": {
        "self_ref_freq": 1,
        "second_person_freq": 0,
        "token_count": 44,
        "self_ref_ratio": 0.022727272727272728,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 0,
        "adj_adv_ratio": 0.0,
        "self_ref_freq": 1,
        "self_ref_ratio": 0.022727272727272728,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 44
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 14.666666666666666,
          "clause_complexity": 0.6666666666666666,
          "vocabulary_richness": 1.0
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 1
          },
          "discourse_markers": {
            "elaboration": 0,
            "contrast": 0,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VB": 2,
            "VBZ": 4,
            "VBN": 1,
            "VBG": 1
          },
          "named_entities": {
            "ORGANIZATION": 1
          }
        }
      },
      "expressive_label": 0,
      "anthropomorphic_label": 0
    },
    {
      "from": "gpt",
      "value": "Yes, that's correct. When the chimeric antigen receptor (CAR) on the surface of the CAR T cells binds to the tumor-specific antigen (TSA) on the surface of cancer cells, it triggers a signaling cascade that ultimately leads to the destruction of the cancer cells.\n\nThe binding of the CAR to the TSA changes the conformation of the intracellular signaling domains of the CAR, which triggers the activation of downstream signaling pathways in the T cells. This results in the release of cytokines and the cytotoxic killing of the cancer cells.\n\nThe signaling pathways activated by the CAR vary depending on the design of the CAR, but typically involve the recruitment and activation of proteins such as CD3Î¶, CD28, and 4-1BB. These proteins activate downstream signaling molecules such as PI3K, Akt, and MAPK, which ultimately lead to the activation of cytotoxic effector mechanisms, such as the release of cytokines and the destruction of the cancer cells.\n\nOverall, the CAR triggers a signaling cascade in the T cells that leads to the destruction of cancer cells expressing the TSA, and this process is dependent on the specific design and configuration of the CAR.",
      "language": "en",
      "sentiment": {
        "neg": 0.162,
        "neu": 0.829,
        "pos": 0.008,
        "compound": -0.9887
      },
      "core_lexical": {
        "self_ref_freq": 0,
        "second_person_freq": 0,
        "token_count": 215,
        "self_ref_ratio": 0.0,
        "second_person_ratio": 0.0
      },
      "lexical_features": {
        "adj_adv_freq": 15,
        "adj_adv_ratio": 0.06976744186046512,
        "self_ref_freq": 0,
        "self_ref_ratio": 0.0,
        "second_person_freq": 0,
        "second_person_ratio": 0.0,
        "token_count": 215
      },
      "advanced_features": {
        "structural_features": {
          "avg_sentence_length": 30.714285714285715,
          "clause_complexity": 0.14285714285714285,
          "vocabulary_richness": 0.5567010309278351
        },
        "interaction_features": {
          "question_types": {
            "what": 0,
            "how": 0,
            "why": 0,
            "can_could": 0,
            "general": 0
          },
          "discourse_markers": {
            "elaboration": 3,
            "contrast": 1,
            "causality": 0,
            "hedging": 0
          }
        },
        "linguistic_features": {
          "verb_tense_dist": {
            "VBZ": 9,
            "VBG": 6,
            "VBN": 1,
            "VB": 1,
            "VBP": 2
          },
          "named_entities": {
            "ORGANIZATION": 15,
            "PERSON": 1
          }
        }
      }
    }
  ],
  "overall_sentiment": {
    "compound": 0.21252307692307695,
    "pos": 0.08923076923076922,
    "neu": 0.8650000000000002,
    "neg": 0.04561538461538461
  },
  "overall_lexical": {
    "adj_adv_freq": 197,
    "adj_adv_ratio": 0.11011738401341531,
    "self_ref_freq": 2,
    "self_ref_ratio": 0.0011179429849077697,
    "second_person_freq": 0,
    "second_person_ratio": 0.0,
    "total_tokens": 1789
  },
  "overall_advanced": {
    "structural_features": {
      "avg_sentence_length": 21.010714285714283,
      "clause_complexity": 0.12945665445665444,
      "vocabulary_richness": 0.7788177668211052
    },
    "interaction_features": {
      "question_types": {
        "what": 0,
        "how": 3,
        "why": 0,
        "can_could": 14,
        "general": 5
      },
      "discourse_markers": {
        "elaboration": 14,
        "contrast": 8,
        "causality": 1,
        "hedging": 0
      }
    },
    "linguistic_features": {
      "verb_tense_dist": {
        "VBZ": 79,
        "VBN": 48,
        "VBG": 43,
        "VBP": 24,
        "VB": 58,
        "VBD": 3
      },
      "named_entities": {
        "GPE": 2,
        "ORGANIZATION": 71,
        "PERSON": 2
      }
    }
  },
  "conversation_metadata": {
    "language_distribution": {
      "en": 13
    },
    "turn_count": 13,
    "total_tokens": 1789
  }
}